Patents
Literature
2 results about "Interferon tau" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Interferon tau is a Type I interferon made up of a single chain of amino-acids. In many species of ruminant, it acts as a signaling molecule during pregnancy. It is secreted by the trophoblast cells into the uterine lumen in days 13-21 of pregnancy. It decreases endometrial oxytocin receptors, which then cannot stimulate PGF-2-alpha synthesis, preventing luteolysis. It promotes uterine implantation by increasing protein synthesis in glands. Although its role in humans is not certain, it has been found to bind to the same receptors sensitive to interferon alpha, and thus may have anti-viral properties, as hinted by studies showing its ability to inhibit the reverse transcriptase enzyme found in retroviruses such as HIV. Its low toxicity compared to other interferons also supports its investigation as a potential therapeutic compound.
Treatments for eye disorders
The present invention is directed to compositions for oral administration comprising two or more active ingredients selected from the group consisting of quercetin, metabolites, derivatives and salts and hydrates thereof, a kaempferol rutinoside and salts and hydrates thereof, indole-3-carbinol and derivatives and metabolites and salts and hydrates thereof and gallic acid and salts and hydrates thereof. The present invention is further directed to methods for treating dry eye disease, treating age-related macular degeneration, increasing Bruch's membrane stiffness, modulating expression of a gene selected from the group consisting of YAP, TAZ, integrin α5, integrin β5, interferon β1, interleukin-6, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 10, and combinations thereof, increasing adhesion of retinal pigment epithelium cells to a Bruch's membrane, and methods of modulating a secretory profile of senescent cells exhibiting the senescence-associated secretory phenotype comprising administering an effective amount of one or more active ingredients selected from the group consisting of kaempferol derivatives and salts thereof and hydrates thereof, quercetin metabolites, derivatives and salts and hydrates thereof, indole-3-carbinol and derivatives and metabolites and salts and hydrates thereof and gallic acid and salts and hydrates thereof to a subject in need thereof.
Owner:PS THERAPY INC
Stem cell exosome preparation for xerophthalmia or eye ulcer and preparation method of stem cell exosome preparation
ActiveCN121320239ASenses disorderSkeletal/connective tissue cellsChromatography columnSize-exclusion chromatography
The invention discloses a stem cell exosome preparation for xerophthalmia or eye ulcer and a preparation method of the stem cell exosome preparation, and belongs to the technical field of biological medicine. The method comprises the following steps: carrying out low-intensity ultrasonic pulse treatment on the mesenchymal stem cells by adopting a pretreatment culture medium containing interferon-gamma and tumor necrosis factor-alpha; removing the pretreated culture medium, replacing the pretreated culture medium with a serum-free culture medium for continuous culture, collecting a culture solution, performing differential centrifugation, and collecting supernate; concentrating the supernate by using a tangential flow filtration system to obtain a concentrated solution; and loading the sample to a size exclusion chromatographic column for purification, and collecting an eluent to obtain the stem cell exosome. The invention discloses a stem cell exosome preparation for xerophthalmia or eye ulcer and a preparation method of the stem cell exosome preparation. A novel biological preparation which can be produced on a large scale and is safe and effective is provided for clinical treatment of xerophthalmia and corneal ulcer.
Owner:ANHUI KEMEN BIOTECHNOLOGY CO LTD